Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

被引：0

作者：

James Yarmolinsky

Emmanouil Bouras

Andrei Constantinescu

Kimberley Burrows

Caroline J. Bull

Emma E. Vincent

Richard M. Martin

Olympia Dimopoulou

Sarah J. Lewis

Victor Moreno

Marijana Vujkovic

Kyong-Mi Chang

Benjamin F. Voight

Philip S. Tsao

Marc J. Gunter

Jochen Hampe

Andrew J. Pellatt

Paul D. P. Pharoah

Robert E. Schoen

Steven Gallinger

Mark A. Jenkins

Rish K. Pai

Dipender Gill

Kostas K. Tsilidis

机构：

[1] University of Bristol,MRC Integrative Epidemiology Unit

[2] Bristol Medical School,Population Health Sciences

[3] University of Bristol,Department of Hygiene and Epidemiology

[4] University of Ioannina Medical School,School of Translational Health Sciences

[5] University of Bristol,NIHR Bristol Biomedical Research Centre

[6] University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol,Biomarkers and Susceptibility Unit, Oncology Data Analytics Program

[7] Catalan Institute of Oncology (ICO),Colorectal Cancer Group, ONCOBELL Program

[8] L’Hospitalet de Llobregat,Department of Clinical Sciences, Faculty of Medicine

[9] Bellvitge Biomedical Research Institute (IDIBELL),Department of Medicine

[10] L’Hospitalet de Llobregat,Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

[11] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP),Department of Genetics

[12] University of Barcelona,Institute of Translational Medicine and Therapeutics

[13] Corporal Michael J. Crescenz VA Medical Center,Department of Medicine

[14] University of Pennsylvania Perelman School of Medicine,Stanford Cardiovascular Institute

[15] University of Pennsylvania,Nutrition and Metabolism Section, International Agency for Research on Cancer

[16] Perelman School of Medicine,Department of Medicine I

[17] University of Pennsylvania,Department of Public Health and Primary Care

[18] University of Pennsylvania,Department of Medicine and Epidemiology

[19] VA Palo Alto Epidemiology Research and Information Center for Genomics,Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital

[20] VA Palo Alto Health Care System,Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health

[21] Stanford University School of Medicine,Department of Laboratory Medicine and Pathology

[22] Stanford University School of Medicine,Department of Epidemiology and Biostatistics, School of Public Health

[23] World Health Organization,undefined

[24] University Hospital Dresden,undefined

[25] Technische Universität Dresden (TU Dresden),undefined

[26] University of Texas MD Anderson Cancer Center,undefined

[27] University of Cambridge,undefined

[28] University of Pittsburgh Medical Center,undefined

[29] University of Toronto,undefined

[30] The University of Melbourne,undefined

[31] Mayo Clinic Arizona,undefined

[32] Imperial College London,undefined

[33] St Mary’s Campus,undefined

来源：

Diabetologia | 2023年 / 66卷

关键词：

ABCC8; Breast cancer; Colorectal cancer; GLP1R; Glucose-lowering drug targets; Mendelian randomisation; PPARG; Prostate cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1481 / 1500

页数：19

共 50 条

[31] Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study
Yan, Zhaoqi
Xu, Yifeng
Li, Keke
Liu, Liangji
ACTA NEUROLOGICA BELGICA, 2024, 124 (02) : 485 - 494
[32] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
C. J. Currie
C. D. Poole
E. A. M. Gale
Diabetologia, 2009, 52 : 1766 - 1777
[33] Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations
Johnson, J. A.
Yasui, Y.
DIABETOLOGIA, 2010, 53 (09) : 1823 - 1826
[34] Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations
J. A. Johnson
Y. Yasui
Diabetologia, 2010, 53 : 1823 - 1826
[35] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J.
Poole, C. D.
Gale, E. A. M.
DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777
[36] Drug repositioning and ovarian cancer, a study based on Mendelian randomisation analysis
Zhu, Lin
Zhang, Hairong
Zhang, Xiaoyu
Chen, Ruoqing
Xia, Lei
FRONTIERS IN ONCOLOGY, 2024, 14
[37] Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study
Zhaoqi Yan
Yifeng Xu
Keke Li
Liangji Liu
Acta Neurologica Belgica, 2024, 124 : 485 - 494
[38] Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis
Fang, Chuchun
Liu, Xuewei
Yu, Chen
Li, Songlin
Liu, Xueying
Qiu, Shifeng
Liang, Hongbin
Ou, Caiwen
Xiu, Jiancheng
JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
[39] Association between genetically proxied glucosamine and risk of cancer and non-neoplastic disease: A Mendelian randomization study
Wu, Yingtong
Che, Yinggang
Zhang, Yong
Xiong, Yanlu
Shu, Chen
Jiang, Jun
Li, Gaozhi
Guo, Lin
Qiao, Tianyun
Li, Shuwen
Li, Ou
Chang, Ning
Zhang, Xinxin
Zhang, Minzhe
Qiu, Dan
Xi, Hangtian
Li, Jinggeng
Chen, Xiangxiang
Ye, Mingxiang
Zhang, Jian
FRONTIERS IN GENETICS, 2024, 15
[40] Causal effects of lipid-lowering drugs on inflammatory skin diseases: Evidence from drug target Mendelian randomisation
Zang, Chenyang
Li, Jiaxin
Zhang, Ying
Deng, Wenyu
Mao, Manyun
Zhu, Wu
Chen, Wangqing
EXPERIMENTAL DERMATOLOGY, 2024, 33 (09)

← 1 2 3 4 5 →